Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Bamlanivimab/etesevimab  COVID-19 treatment studies for Bamlaniv../e..  C19 studies: Bamlaniv../e..  Bamlaniv../e..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -119% Improvement Relative Risk Hospitalization 52% Progression 20% Delasobera et al. Bamlanivimab/e.. for COVID-19 EARLY Is early treatment with bamlanivimab/etesevimab beneficial for COVID-19? Retrospective 438 patients in the USA Lower hospitalization with bamlanivimab/etesevimab (p=0.014) Delasobera et al., Infectious Diseases in Clinic.., doi:10.1097/IPC.0000000000001109 Favors bamlanivimab/e.. Favors control
Impact of Rapidly Deployed COVID-19 Monoclonal Antibody Infusion Clinics on Rate of Hospitalization
Delasobera et al., Infectious Diseases in Clinical Practice, doi:10.1097/IPC.0000000000001109
Delasobera et al., Impact of Rapidly Deployed COVID-19 Monoclonal Antibody Infusion Clinics on Rate of Hospitalization, Infectious Diseases in Clinical Practice, doi:10.1097/IPC.0000000000001109
Jan 2022   Source   PDF  
  All Studies   Meta
Retrospective 438 patients in the USA, 253 treated with bamlanivimab, showing significantly lower hospitalization with treatment.
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, VanBlargan].
risk of death, 119.4% higher, RR 2.19, p = 0.64, treatment 3 of 253 (1.2%), control 1 of 185 (0.5%).
risk of hospitalization, 52.2% lower, RR 0.48, p = 0.01, treatment 17 of 253 (6.7%), control 26 of 185 (14.1%), NNT 14.
risk of progression, 19.9% lower, RR 0.80, p = 0.52, treatment 23 of 253 (9.1%), control 21 of 185 (11.4%), NNT 44, ER followup visit.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Delasobera et al., 27 Jan 2022, retrospective, USA, peer-reviewed, 12 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperBamlaniv../e..All
Abstract: ORIGINAL ARTICLE Impact of Rapidly Deployed COVID-19 Monoclonal Antibody Infusion Clinics on Rate of Hospitalization Bronson E. Delasobera, MD,* Tara Saggar, MD,* Jennifer N. Goodwin, MBA,* Amanda Joy, MS, PA-C,* Kiersten N. Henry, DNP, ACNP-BC,* Bonnie Levin, PharmD, MBA,* David D. Hager, MD,* Joel McAlduff, MD,* Sameer DeSale, PhD,* Xavier Owens, MHSA,* Glenn W. Wortmann, MD,† and Princy N. Kumar, MD‡ Background: Providing monoclonal antibody therapy infusions requires challenging logistics, resources, and technology, hindering availability across the United States. Early identification and treatment of COVIDpositive patients can reduce hospitalizations. Objective: This study aimed to describe the referral, selection process, and deployment of outpatient monoclonal infusion clinics, as well as the impact of monoclonal antibody therapy in COVID-positive patients on the rate of emergency department (ED) visits and hospitalization. Methods: This is a retrospective cohort study that used screening of all COVID-positive ambulatory patients using a unique scoring rubric embedded in the emergency medical response for appropriateness for therapy between November 2020 and January 2021. Participants included all outpatients testing positive for COVID-19 were screened, and those eligible were referred for treatment with bamlanivimab. Of the 443 patients referred for treatment, 252 patients were treated with bamlanivimab compared with 191 patients who declined treatment. Patients were treated either in 1 of the 2 outpatient infusion centers (74%) or the ED (26%.) Results: Of 443 patients with positive COVID-19 diagnoses who were eligible for treatment based on a risk assessment rubric, 252 received bamlanivimab. There was a significant reduction in hospitalization of the treatment versus control group (6.7% vs 13.6%, P < 0.05). No significant differences were noted in risk score at screening, ED visits after infusion, days of symptom onset at screening or infusion, or death. Conclusions and Relevance: The efficacy of monoclonal antibody therapy on reducing hospitalization was demonstrated. Rapid development of screening technology, scheduling and operational logistics, and physical space can overcome the challenges in the current environment. Key Words: COVID-19, monoclonal antibody therapy, infusion (Infect Dis Clin Pract 2022;30: e1109) A major focus of the initial treatment of COVID-19 was to limit disease progression in the inpatient setting. However, as the pandemic progressed, the need for outpatient treatment options became apparent. In November 2020, the Food and Drug Administration From the *MedStar Health; †MedStar Washington Hospital Center; and ‡Georgetown University Medical Center, Washington, DC. Correspondence to: Princy N. Kumar, MD, Georgetown University School of Medicine, 5th Floor PHC Building, 3800 Reservoir Rd NW, Washington, DC 20007. E‐mail: B.E.D., T.S., J.N.G., A.J., K.N.H., B.L., D.D.H., J.M., S.D., X.O., and G.W.W. report no conflicts of interest. P.N.K. reports receipt of grants/research supports from Eli Lilly, Merck, Gilead, and GSK; reports receipt of honoraria or consultation fees from Gilead, GSK, Merck, and AMGEN; and is a stock shareholder of Pfizer, Johnson & Johnson, Gilead, Merck, and GSK. Copyright ©..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop